OncoMed Pharma (OMED) Reports Q2 Loss Per Share of 72c, Maintains FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OncoMed Pharmaceuticals Announces Second Quarter 2015 Financial Results and Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
August 10, 2015 4:16 PM EDTREDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED) today reported financial results for the quarter ended June 30, 2015 and provided an update on progress toward 2015 corporate objectives and clinical development milestones, including new data from the Phase 1b clinical trial of demcizumab in non-small cell lung cancer (NSCLC).
"OncoMed's second quarter highlighted data from several presentations at the American Academy of Cancer Research and American Society of Clinical Oncology annual meetings, including positive results from our Phase 1b demcizumab and... More
